Abstract:Background Spinocerebellar ataxia type 3 (SCA3) is the most common subtype of autosomal dominantly inherited spinocerebellar ataxias (SCAs). No validated blood biomarker is available to assess either disease progression or therapeutic response. Neurofilament light chain (NfL) was recently proposed as a serum biomarker for many neurodegenerative disorders. The present study investigated whether NfL was a promising serum biomarker for SCA3. Methods Seventeen SCA3 patients and 9 controls were enrolled in cohort A, and 116 SCA3 individuals (preclinical and patients) and 91 controls were recruited as cohort B. We assessed whether serum NfL correlated with cerebrospinal fluid (CSF) NfL in cohort A and correlations between serum NfL levels and clinical features and brain volumes were determined in cohort B. The single-molecule array method was used to measure serum NfL levels. Disease severity was determined using the scale for the assessment and rating of ataxia (SARA) and the international cooperative ataxia rating scale (ICARS). Cerebellar and brainstem volumes were assessed using MRI neuroimaging measurements. Results Serum/CSF NfL levels in cohort A were elevated in SCA3 patients, and serum and CSF NfL exhibited a significant positive correlation ( r = 0.9179, p < 0.0001). Levels of serum NfL in cohort B were significantly higher in preclinical SCA3 (15.03 ± 7.49 vs 6.88 ± 2.72 pg/ mL, p < 0.0001) and manifest SCA3 subjects (37.56 ± 13.47 vs 9.07 ± 6.02 pg/ mL, p < 0.0001) compared to those in controls. Serum NfL concentrations increased from early disease stage to the next stage. Levels of serum NfL in ATXN3 mutation carriers were positively associated with SARA ( r = 0.5458, p < 0.0001) and ICARS scores ( r = 0.5522, p < 0.0001). Significant negative associations with cerebellar volumes ( r = − 0.4217, p = 0.0003) and brainstem volumes ( r = − 0.4263, p = 0.0003) were observed. All changes remained significant after adjustment for age and CAG repeat. Conclusions Levels of serum NfL were significantly elevated in SCA3 individuals and correlated with disease severity. Serum NfL is a promising serum biomarker of disease onset and progression, and a potential candidate biomarker of treatment response in SCA3.

Serum Neurofilament Light Chain in Wilson's Disease: A Promising Indicator but Unparallel to Real‐Time Treatment Response

Plasma Neurofilament Light Chain As a Biomarker in Wilson's Disease

Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.

Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3

The potential of serum neurofilament as biomarker for multiple sclerosis

Serum ceruloplasmin oxidase activity: A neglected diagnostic biomarker for Wilson disease

Serum Neurofilament Light Predicts Severity and Prognosis in Patients with Ischemic Stroke

Serum Neurofilament Dynamics Predicts Cognitive Progression in De Novo Parkinson's Disease.

Serum Neurofilament Light Chain Levels May Be a Marker of Lower Motor Neuron Damage in Amyotrophic Lateral Sclerosis

High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis

Role of Serum NFL in Parkinson's Disease: Evolution, Diagnosis, and Prognosis

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Application Value of Serum Neurofilament Light Protein for Disease Staging in Huntington's Disease

Neuroimaging Correlates with Clinical Severity in Wilson Disease: A Multiparametric Quantitative Brain MRI

Serum neurofilament light as a potential marker of illness duration in bipolar disorder

Serum neurofilament light chain: a predictive marker for outcomes following mild-to-moderate ischemic stroke

Neurofilament light chain as a biomarker in neurological disorders

Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3

Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice

Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

Serum Neurofilament and Free Light Chain Levels in Patients Undergoing Treatment for Chronic Inflammatory Demyelinating Polyneuropathy